What we are studying
The purpose of this study is to gather information on whether PRM-151 has an effect on your MF disease, whether it is safe in patients with MF, and how well it is tolerated (that is, whether or not it makes you feel ill. Approximately 84 subjects with MF will take part in this study in study centers in the United States, Canada and Europe. Each subject will participate in the study for approximately 44 weeks. These 44 weeks include: the screening period, which will begin approximately 28 days before the first PRM-151dose is given; a study period (when you receive the PRM-151 infusions) of 36 weeks and a follow up period (after you are done with PRM-151 infusions). During the 36 week study period, you will have up to 11 outpatient visits. During the follow-up period, one visit approximately 29 days after your last infusion and one more at about 28 days after your last visit, or approximately 60 days after your last infusion of the study drug, for a total of 2 visits during the follow-up period.
none, however the Comprehensive Cancer Center of CepEsperu University will provide you with a parking voucher for your study related visits.